Citigroup Inc Arbutus Biopharma Corp Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 10, 2024	SELL	$2.26 - $2.92 $1 Million - $1.3 Million	-444,000 Reduced 65.39%	235,000 $606,000
Q4 2023 Feb 09, 2024	BUY	$1.69 - $2.54 $818,974 - $1.23 Million	484,600 Added 249.28%	679,000 $1.7 Million
Q3 2023 Nov 09, 2023	SELL	$1.9 - $2.27 $158,650 - $189,545	-83,500 Reduced 30.05%	194,400 $394,000
Q2 2023 Aug 10, 2023	BUY	$2.24 - $3.06 $211,456 - $288,864	94,400 Added 51.44%	277,900 $639,000
Q1 2023 May 11, 2023	BUY	$2.23 - $3.1 $409,205 - $568,850	183,500 New	183,500 $556,000

Q1 2022 May 12, 2022	BUY	$2.42 - $3.98 $58,564 - $96,316	24,200 New	24,200 $72,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.